Novo Nordisk terminates collaboration with Hims & Hers Health
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2025
0mins
Should l Buy NVO?
Collaboration Halted: Novo Nordisk has ended its partnership with Hims & Hers Health, resulting in the discontinuation of direct access to Wegovy through the NovoCare Pharmacy.
Market Impact: Following the announcement, shares of Hims & Hers Health dropped approximately 18% in pre-market trading.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 36.480
Low
42.00
Averages
54.67
High
70.00
Current: 36.480
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's New Drug Could Dominate Weight Loss Market
- Intensified Drug Competition: Eli Lilly's new drug Foundayo (orforglipron) is set to launch on April 6, positioning it to fiercely compete with Novo Nordisk's Wegovy, potentially dominating the anti-obesity drug market for the next several years.
- Significant Clinical Trial Results: In its first phase 3 trial, patients taking the 12mg dose of retatrutide lost an average of 28.7% of body weight over 68 weeks, showcasing its potential in the weight loss drug arena, surpassing Novo Nordisk's CagriSema.
- Strong Market Demand: Early indications for Novo Nordisk's oral formulation of Wegovy suggest a robust appetite for anti-obesity drugs, while orforglipron's lack of dietary restrictions may enable it to outsell Wegovy, catering to consumer preferences for convenient weight loss solutions.
- Optimistic Industry Outlook: With the dual advantages of orforglipron and retatrutide, Eli Lilly is poised to maintain a competitive edge over Novo Nordisk in the coming years, potentially reshaping the landscape of the anti-obesity drug market.
See More
Novo Nordisk and Eli Lilly Battle for Obesity Drug Market Control
- Intensifying Market Competition: Novo Nordisk's Wegovy received approval in December as the first GLP-1 weight-loss pill, while Eli Lilly's new drug orforglipron is set to launch on April 6, marking a new phase in the competition between these two companies in the rapidly growing obesity drug market.
- Medication Convenience Comparison: Orforglipron has no food or water restrictions, whereas Wegovy must be taken on an empty stomach, requiring patients to avoid food and other medications for 30 minutes prior, which could affect patient adherence and subsequently impact sales performance.
- Potential Market Opportunity: Early demand for Novo Nordisk's oral formulation of Wegovy indicates a strong appetite for non-injectable obesity drugs, and Eli Lilly's orforglipron is expected to leverage its convenience to gain market share.
- Future Competitive Landscape: Eli Lilly's retatrutide shows promising results in phase 3 trials with an average weight loss of 28.7%, while Novo Nordisk's CagriSema only achieved a 23% reduction, suggesting that Eli Lilly may maintain a competitive edge in obesity drug development, continuing to pressure Novo Nordisk in the market.
See More
Novo Nordisk and Eli Lilly Battle for Obesity Drug Market Control
- Intensifying Market Competition: Novo Nordisk's Wegovy received approval in December as the first GLP-1 weight-loss pill, while Eli Lilly's orforglipron is set to launch on April 6, marking a new phase in their rivalry in the obesity drug market.
- Product Advantage Comparison: Orforglipron's lack of food and water restrictions may make it more appealing to consumers compared to Wegovy's requirement for fasting, potentially boosting Eli Lilly's sales prospects in the market.
- Clinical Trial Data: Eli Lilly's retatrutide showed strong competitive potential in phase 3 trials, with patients losing an average of 28.7% of body weight over 68 weeks on a 12mg dose, while Novo Nordisk's CagriSema only achieved a 23% reduction, failing to meet non-inferiority standards.
- Future Development Challenges: Novo Nordisk faces long drug development timelines, with its next potential product still years away from market, allowing Eli Lilly to capitalize on orforglipron and retatrutide in the interim.
See More
Middle East Conflict Disrupts Tourism Industry
- Flight Cancellations Surge: Over 46,000 flights to and from the Middle East have been canceled since the U.S.-Israel conflict began, posing significant operational challenges for airlines and destabilizing the global aviation market.
- High Airfare Affects Travel Plans: Vietnamese traveler Michelle Bui canceled her trip to the Middle East due to soaring ticket prices ranging from $1,500 to $2,000, highlighting the direct impact of the conflict on travel demand.
- Corporate Travel Strategy Adjustments: Voluntary flight cancellations on Europe-Asia routes more than doubled in the first week of March due to safety concerns, indicating that companies are reassessing employee travel safety, which affects the frequency of business trips.
- Regional Travel Gains Popularity: Ferry travel from Singapore to Batam, Indonesia, remains popular despite a $4.66 fuel surcharge, reflecting the appeal of regional travel options as Asian travelers prefer short getaways over long-haul flights.
See More
Novo Nordisk Launches Wegovy Subscription Plan to Regain Market Share
- Market Share Challenge: Novo Nordisk has lost its leading position in the anti-obesity market to Eli Lilly, and despite launching new drugs and label expansions, the market penetration remains insufficient, indicating increasing competitive pressure.
- Obesity Patient Status: Approximately 40.3% of adults in the U.S. are classified as obese, but some studies suggest this figure could be as high as 70%, highlighting a significant potential market; however, only 12% of patients are currently using GLP-1 drugs, revealing a substantial opportunity.
- New Subscription Plan: Novo Nordisk has introduced a subscription plan for Wegovy lasting three, six, or twelve months, allowing patients to access discounts through telehealth platforms, aiming to enhance drug accessibility and expand market reach.
- Future Outlook: While Novo Nordisk's subscription plan may not fully reclaim market share, its pipeline progress and relatively low valuation (11x forward earnings) could present an attractive opportunity for investors, especially as growth is expected to rebound in the coming years.
See More
Novo Nordisk Launches New Subscription Model to Expand Market Reach
- Market Potential: Research indicates that approximately 70% of adults in the U.S. may be obese, yet only 12% are currently using GLP-1 drugs, highlighting significant growth opportunities in the weight loss drug market that Novo Nordisk needs to capitalize on.
- New Subscription Model: Novo Nordisk has introduced a subscription model for Wegovy prescriptions lasting three, six, or twelve months, allowing patients to access lower prescription costs through telehealth platforms, which is expected to significantly enhance drug accessibility and attract more users.
- Competitive Pressure: While Novo Nordisk's subscription model may help expand its market share, the potential for Eli Lilly to adjust its pricing poses uncertainty regarding Novo Nordisk's ability to regain its market leadership position.
- Attractive Valuation: Currently, Novo Nordisk trades at an 11x forward earnings multiple, which is below the healthcare sector average of 17.3x, suggesting that investors purchasing its shares at this level may achieve favorable returns.
See More
Eli Lilly's New Drug Could Dominate Weight Loss Market
- Intensified Drug Competition: Eli Lilly's new drug Foundayo (orforglipron) is set to launch on April 6, positioning it to fiercely compete with Novo Nordisk's Wegovy, potentially dominating the anti-obesity drug market for the next several years.
- Significant Clinical Trial Results: In its first phase 3 trial, patients taking the 12mg dose of retatrutide lost an average of 28.7% of body weight over 68 weeks, showcasing its potential in the weight loss drug arena, surpassing Novo Nordisk's CagriSema.
- Strong Market Demand: Early indications for Novo Nordisk's oral formulation of Wegovy suggest a robust appetite for anti-obesity drugs, while orforglipron's lack of dietary restrictions may enable it to outsell Wegovy, catering to consumer preferences for convenient weight loss solutions.
- Optimistic Industry Outlook: With the dual advantages of orforglipron and retatrutide, Eli Lilly is poised to maintain a competitive edge over Novo Nordisk in the coming years, potentially reshaping the landscape of the anti-obesity drug market.
See More
Novo Nordisk and Eli Lilly Battle for Obesity Drug Market Control
- Intensifying Market Competition: Novo Nordisk's Wegovy received approval in December as the first GLP-1 weight-loss pill, while Eli Lilly's new drug orforglipron is set to launch on April 6, marking a new phase in the competition between these two companies in the rapidly growing obesity drug market.
- Medication Convenience Comparison: Orforglipron has no food or water restrictions, whereas Wegovy must be taken on an empty stomach, requiring patients to avoid food and other medications for 30 minutes prior, which could affect patient adherence and subsequently impact sales performance.
- Potential Market Opportunity: Early demand for Novo Nordisk's oral formulation of Wegovy indicates a strong appetite for non-injectable obesity drugs, and Eli Lilly's orforglipron is expected to leverage its convenience to gain market share.
- Future Competitive Landscape: Eli Lilly's retatrutide shows promising results in phase 3 trials with an average weight loss of 28.7%, while Novo Nordisk's CagriSema only achieved a 23% reduction, suggesting that Eli Lilly may maintain a competitive edge in obesity drug development, continuing to pressure Novo Nordisk in the market.
See More
Novo Nordisk and Eli Lilly Battle for Obesity Drug Market Control
- Intensifying Market Competition: Novo Nordisk's Wegovy received approval in December as the first GLP-1 weight-loss pill, while Eli Lilly's orforglipron is set to launch on April 6, marking a new phase in their rivalry in the obesity drug market.
- Product Advantage Comparison: Orforglipron's lack of food and water restrictions may make it more appealing to consumers compared to Wegovy's requirement for fasting, potentially boosting Eli Lilly's sales prospects in the market.
- Clinical Trial Data: Eli Lilly's retatrutide showed strong competitive potential in phase 3 trials, with patients losing an average of 28.7% of body weight over 68 weeks on a 12mg dose, while Novo Nordisk's CagriSema only achieved a 23% reduction, failing to meet non-inferiority standards.
- Future Development Challenges: Novo Nordisk faces long drug development timelines, with its next potential product still years away from market, allowing Eli Lilly to capitalize on orforglipron and retatrutide in the interim.
See More
Middle East Conflict Disrupts Tourism Industry
- Flight Cancellations Surge: Over 46,000 flights to and from the Middle East have been canceled since the U.S.-Israel conflict began, posing significant operational challenges for airlines and destabilizing the global aviation market.
- High Airfare Affects Travel Plans: Vietnamese traveler Michelle Bui canceled her trip to the Middle East due to soaring ticket prices ranging from $1,500 to $2,000, highlighting the direct impact of the conflict on travel demand.
- Corporate Travel Strategy Adjustments: Voluntary flight cancellations on Europe-Asia routes more than doubled in the first week of March due to safety concerns, indicating that companies are reassessing employee travel safety, which affects the frequency of business trips.
- Regional Travel Gains Popularity: Ferry travel from Singapore to Batam, Indonesia, remains popular despite a $4.66 fuel surcharge, reflecting the appeal of regional travel options as Asian travelers prefer short getaways over long-haul flights.
See More
Novo Nordisk Launches Wegovy Subscription Plan to Regain Market Share
- Market Share Challenge: Novo Nordisk has lost its leading position in the anti-obesity market to Eli Lilly, and despite launching new drugs and label expansions, the market penetration remains insufficient, indicating increasing competitive pressure.
- Obesity Patient Status: Approximately 40.3% of adults in the U.S. are classified as obese, but some studies suggest this figure could be as high as 70%, highlighting a significant potential market; however, only 12% of patients are currently using GLP-1 drugs, revealing a substantial opportunity.
- New Subscription Plan: Novo Nordisk has introduced a subscription plan for Wegovy lasting three, six, or twelve months, allowing patients to access discounts through telehealth platforms, aiming to enhance drug accessibility and expand market reach.
- Future Outlook: While Novo Nordisk's subscription plan may not fully reclaim market share, its pipeline progress and relatively low valuation (11x forward earnings) could present an attractive opportunity for investors, especially as growth is expected to rebound in the coming years.
See More
Novo Nordisk Launches New Subscription Model to Expand Market Reach
- Market Potential: Research indicates that approximately 70% of adults in the U.S. may be obese, yet only 12% are currently using GLP-1 drugs, highlighting significant growth opportunities in the weight loss drug market that Novo Nordisk needs to capitalize on.
- New Subscription Model: Novo Nordisk has introduced a subscription model for Wegovy prescriptions lasting three, six, or twelve months, allowing patients to access lower prescription costs through telehealth platforms, which is expected to significantly enhance drug accessibility and attract more users.
- Competitive Pressure: While Novo Nordisk's subscription model may help expand its market share, the potential for Eli Lilly to adjust its pricing poses uncertainty regarding Novo Nordisk's ability to regain its market leadership position.
- Attractive Valuation: Currently, Novo Nordisk trades at an 11x forward earnings multiple, which is below the healthcare sector average of 17.3x, suggesting that investors purchasing its shares at this level may achieve favorable returns.
See More
